AIMS: Data on glucose and cardiovascular disease (CVD) risk factor control among persons with type 2 diabetes mellitus (DM) according to insulin treatment status are lacking. We examined DM control, risk factors, and comorbidities among U.S. persons according to insulin treatment status. METHODS: In the U.S. National Health and Nutrition Examination Surveys 2003-2006, we examined in 10,637 adults aged ≥30 with type 2 DM the extent of control of A1c, LDL-C, HDL-C, triglycerides, and blood pressure (BP) and composite goal attainment by insulin use status. RESULTS: 6.6% (n=889, projected to 14.3 million) had type 2 DM; of these, 22.9% were insulin users and 57.2% were treated only by other diabetes medications. Overall, 58.2% had an A1c<7% (53 mmol/mol) (insulin users 33.1%, non-insulin treated 66.1%, and 77.9% of those not on medication, p<0.0001). Overall, 44.2% were at a BP goal of <130/80 mmHg, 43.8% had an LDL-C<100 mg/dl (2.6 mmol/L), and 13.9% a BMI<25 kg/m(2). Only 10.2% were simultaneously at A1c, LDL, and BP goals (5.4% of those on insulin). CONCLUSIONS: U.S. adults with type 2 DM, especially those treated with insulin remain inadequately controlled for A1c and CVD risk factors and have a high prevalence of comorbidities.
AIMS: Data on glucose and cardiovascular disease (CVD) risk factor control among persons with type 2 diabetes mellitus (DM) according to insulin treatment status are lacking. We examined DM control, risk factors, and comorbidities among U.S. persons according to insulin treatment status. METHODS: In the U.S. National Health and Nutrition Examination Surveys 2003-2006, we examined in 10,637 adults aged ≥30 with type 2 DM the extent of control of A1c, LDL-C, HDL-C, triglycerides, and blood pressure (BP) and composite goal attainment by insulin use status. RESULTS: 6.6% (n=889, projected to 14.3 million) had type 2 DM; of these, 22.9% were insulin users and 57.2% were treated only by other diabetes medications. Overall, 58.2% had an A1c<7% (53 mmol/mol) (insulin users 33.1%, non-insulin treated 66.1%, and 77.9% of those not on medication, p<0.0001). Overall, 44.2% were at a BP goal of <130/80 mmHg, 43.8% had an LDL-C<100 mg/dl (2.6 mmol/L), and 13.9% a BMI<25 kg/m(2). Only 10.2% were simultaneously at A1c, LDL, and BP goals (5.4% of those on insulin). CONCLUSIONS: U.S. adults with type 2 DM, especially those treated with insulin remain inadequately controlled for A1c and CVD risk factors and have a high prevalence of comorbidities.
Authors: Giuseppina Imperatore; Betsy L Cadwell; Linda Geiss; Jinan B Saadinne; Desmond E Williams; Earl S Ford; Theodore J Thompson; K M Venkat Narayan; Edward W Gregg Journal: Am J Epidemiol Date: 2004-09-15 Impact factor: 4.897
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Anthony Keech; David Colquhoun; James Best; Adrienne Kirby; R John Simes; David Hunt; Wendy Hague; Elaine Beller; Manjula Arulchelvam; Jennifer Baker; Andrew Tonkin Journal: Diabetes Care Date: 2003-10 Impact factor: 19.112
Authors: Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling Journal: Lancet Date: 1998-06-13 Impact factor: 79.321
Authors: Fadia T Shaya; Xia Yan; Pei-Jung Lin; Linda Simoni-Wastila; Morgan Bron; Robert Baran; Thomas W Donner Journal: J Clin Hypertens (Greenwich) Date: 2010-10 Impact factor: 3.738
Authors: Sayeed Ikramuddin; Charles J Billington; Wei-Jei Lee; John P Bantle; Avis J Thomas; John E Connett; Daniel B Leslie; William B Inabnet; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael G Sarr; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Joyce L Schone; Amy E Olofson; Heather A Bainbridge; Patricia S Laqua; Qi Wang; Judith Korner Journal: Lancet Diabetes Endocrinol Date: 2015-05-12 Impact factor: 32.069
Authors: David E Cummings; David E Arterburn; Emily O Westbrook; Jessica N Kuzma; Skye D Stewart; Chun P Chan; Steven N Bock; Jeffrey T Landers; Mario Kratz; Karen E Foster-Schubert; David R Flum Journal: Diabetologia Date: 2016-03-17 Impact factor: 10.122
Authors: Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; John E Connett; William B Inabnet; Charles J Billington; Avis J Thomas; Daniel B Leslie; Keong Chong; Robert W Jeffery; Leaque Ahmed; Adrian Vella; Lee-Ming Chuang; Marc Bessler; Michael G Sarr; James M Swain; Patricia Laqua; Michael D Jensen; John P Bantle Journal: JAMA Date: 2013-06-05 Impact factor: 56.272
Authors: Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; Avis J Thomas; John E Connett; John P Bantle; Daniel B Leslie; Qi Wang; William B Inabnet; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Charles J Billington Journal: JAMA Date: 2018-01-16 Impact factor: 56.272
Authors: Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; John P Bantle; Avis J Thomas; John E Connett; Daniel B Leslie; William B Inabnet; Qi Wang; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Amy E Olofson; Heather A Bainbridge; Charles J Billington Journal: Diabetes Care Date: 2016-06-16 Impact factor: 19.112
Authors: Nathan D Wong; Christopher Patao; Kalina Wong; Shaista Malik; Stanley S Franklin; Uchenna Iloeje Journal: Diab Vasc Dis Res Date: 2013-08-22 Impact factor: 3.291